How to Use Xolair and Omalizumab for Desensitization?
When symptoms or doubts arise involving XolairDistinguishing between scientifically validated information and palliative care makes all the difference in the evolution of respiratory, skin, and systemic health. This page aims to deepen understanding of... "How to Use Xolair and Omalizumab for Desensitization?", providing clear context on how the immune system reacts, which signs require medical attention, and how to structure individualized and effective care.
✔ Medical content reviewed and validated by the founding clinical staff of the Brazil Without Allergies Project
Dr. Marcello Bossois (CRM-RJ 52.73214-1) · Dr. Patricia Schlinkert (CRM/RJ 5274541-3) — more than 30 years of history in Allergy and Immunology, with units in Rio de Janeiro, São Paulo and Paraná. Last reviewed: November 2026.
The Use of Omalizumab as an Ally in Desensitization Protocols
In recent years, the practice of desensitization—a process aimed at inducing tolerance in the body to certain allergens, such as foods or medications—has relied on adjuvant strategies to increase patient safety. Among the resources studied and used by specialists, the use of omalizumab stands out. This is a monoclonal anti-IgE antibody commercially known as Xolair. This medication works by blocking immunoglobulin E, reducing the activation of mast cells, which are the cells responsible for releasing histamine and other inflammatory mediators involved in severe allergic reactions, including anaphylaxis.
The main objective of associating omalizumab with tolerance induction protocols is precisely to mitigate the risks inherent in the procedure, decreasing the likelihood of severe systemic reactions. Furthermore, laboratory monitoring through tryptase measurement—an important marker of mast cell activation—helps physicians monitor the immune response during the process. However, the exact procedure, administration schedules, and dosages may vary according to the protocol of each specialized service.
Safety Considerations and the Hospital Environment
It is crucial to emphasize that desensitization procedures, especially in patients with a history of severe anaphylactic reactions to medications or foods, present inherent risks due to the controlled exposure to the allergen itself. For this reason, such procedures require highly complex infrastructure.
Outpatient clinics and medical offices, being low-complexity units, do not have the advanced life support infrastructure necessary for the immediate care of a severe anaphylactic emergency. Therefore, desensitization must be performed in a hospital setting (usually as an inpatient). In this controlled environment, the patient remains continuously monitored, with intravenous access, a trained multidisciplinary team, intensive care support, and the presence of specialist physicians, such as anesthesiologists, ensuring complete safety throughout the procedure.
Omalizumab Utilization Strategy
In academic settings and in the practice of specialized centers that perform this type of procedure, reports and discussions among professionals point to preventive regimens with omalizumab. Generally, the monoclonal antibody can be administered in fractionated doses—for example, a 600 mg application given approximately two weeks before the start of desensitization, followed by another 600 mg dose 24 hours before the procedure. This is a supportive approach aimed at preparing the immune system, reducing allergic hyperreactivity.
It should be emphasized that this content is strictly educational and informative in nature, and in no way replaces individualized medical evaluation, in-person consultation with a qualified Allergy and Immunology specialist, or precise therapeutic guidance for each clinical case.
Developments in Evidence-Based Medicine: Pharmacology of Immunobiologics and Precision Medicine
In Evidence-Based Medicine, the indication of immunobiological agents (monoclonal antibodies and receptor fusion proteins) It is based on the patient's inflammatory endotyping. Selective blocking of molecular targets — such as the neutralization of free IgE by omalizumab (in severe allergic asthma and chronic spontaneous urticaria refractory to quadrupled-dose H1 antihistamines), the dual inhibition of IL-4 and IL-13 interleukin signaling by dupilumab (In moderate to severe atopic dermatitis, eosinophilic/Th2 asthma, and chronic rhinosinusitis with nasal polyposis), the blockade of the TSLP epithelial alarm by tezepelumab or blocking the IL-5/IL-5R pathway — allows control of the inflammatory cascade at its cellular origin, reducing exacerbations and sparing the patient from the adverse metabolic, endocrine, and cardiovascular effects of prolonged systemic corticosteroid use.
💎 Diamond Plan — Eating safely and without fear of adverse reactions starts with an accurate diagnosis. Speak with an Allergy and Immunology specialist via teleconsultation, from anywhere in Brazil. Schedule a teleconsultation →
Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.
Precision Medicine: How Monoclonal Antibodies and Immunobiologics Work
Selective Blockade of Cytokines (IL-4, IL-5, IL-13, TSLP) and Immunoglobulin E
Monoclonal antibodies (immunobiologics) have revolutionized the management of severe allergic and immune-mediated diseases that do not achieve full control with conventional therapies. Unlike systemic corticosteroids and classic immunosuppressants—which broadly depress immunity and generate metabolic toxicity—immunobiologics act as highly precise molecular keys, neutralizing specific targets of the inflammatory cascade: such as circulating free IgE (omalizumab), the IL-4 and IL-13 receptor (dupilumab), the eosinophilic pathway of IL-5 (mepolizumab and benralizumab), or the epithelial alarmin TSLP (tezepelumab).
Indications Criteria, Allergy Phenotyping, and Associated Therapies
Specialized monitoring integrates laboratory biomarkers, allergy test Targeted management of the upper and lower airways. Depending on the identified endotype, align targeted therapies with established strategies. allergy vaccine and rhinitis treatment It provides sustained clinical remission without the adverse effects of oral corticosteroids.
Difference between Exaggerated Local Reaction, Strophulus, and Anaphylaxis
In allergological practice, distinguishing between local inflammatory edema and a systemic allergic reaction is crucial to protecting the patient's life. In mosquito hypersensitivity, a mixed immune response occurs (immediate mediated by IgE and delayed cellular response by T lymphocytes), causing a single bite to reactivate old lesions throughout the body. In reactions to bees and wasps, symptoms distant from the sting site—such as generalized plaques, hoarseness, bronchospasm, or a drop in blood pressure—characterize anaphylaxis and require immediate intervention.
IgE-Mediated Allergy, Mixed Allergy, and Difference from Enzyme Intolerances
In contemporary allergology, it is essential to differentiate the immunological reaction against food proteins—such as casein, alpha-lactalbumin, and beta-lactoglobulin in cow's milk, ovomucoid in eggs, or tropomyosin in crustaceans—from non-immune digestive intolerances, such as lactase enzyme deficiency. While intolerance causes abdominal distension, flatulence, and osmotic diarrhea restricted to the digestive tract, food allergy involves Th2 lymphocytes and IgE antibodies or eosinophilic cellular inflammation, and can cause acute urticaria, angioedema, bronchospasm, proctocolitis, or anaphylaxis within minutes of ingesting trace amounts.
Epithelial Dysfunction, Skin Microbiome, and Delayed Sensitization
In eczematous dermatitis and cases of chronic pruritus, differentiating constitutional atopy from allergic contact dermatitis (a type IV delayed hypersensitivity reaction mediated by T lymphocytes sensitized to metals, cosmetic preservatives, fragrances, resins, or rubber) is essential. Repeated exposure to the sensitizing agent maintains active skin inflammation even with the use of anti-inflammatory ointments, requiring precise identification of the triggering factor.
Immediate Reactions, Delayed Drug Reactions, and Risks of Self-Medication
Drug hypersensitivity reactions encompass distinct immunological and pharmacological mechanisms: from immediate reactions (up to one to six hours after dosing, manifested by urticaria, labial or palpebral angioedema, bronchospasm, and anaphylaxis, common with COX-1 inhibitor analgesics and beta-lactams) to delayed drug eruptions mediated by T cells, such as maculopapular rashes and DRESS syndrome — a systemic condition that arises weeks after the start of anticonvulsants, sulfones, or allopurinol, presenting with fever, lymphadenomegaly, eosinophilia, and the need for immediate discontinuation under hospital supervision.
Diamond Plan: Specialized Allergy Treatment Wherever You Are
Treating the cause of an allergy requires consistency — and consistency requires access. Diamond Plan It was designed for patients throughout Brazil who face the high cost of allergy vaccines and the difficulties of travel, offering specialized follow-up through telemedicine and easy access to immunotherapy treatment. Eating safely and without fear of reactions starts with an accurate diagnosis.
Why do patients across Brazil choose the Diamond Plan?
- Teleconsultation with a specialist In Allergy and Immunology, without queues and without long commutes — ideal for those who live far from large cities.
- easy access to Immunotherapy (including allergy vaccines and immunostimulants) — indicated for the treatment of allergic rhinitis, asthma, bronchitis, atopic dermatitis, insect/mosquito bite allergy (prurigo strophulus), recurrent candidiasis, and for increasing immunity in selected patients — capable of modifying the natural course of allergic disease, always through consultation and individualized prescription.
- A more accessible route For those facing the high cost of allergy vaccines, this plan offers support for continuity of treatment.
- Continuous monitoring based on clinical evolution, with adjustments to treatment throughout the entire therapeutic cycle.
- National coverage, backed by a consolidated physical network and a founding clinical team with over three decades of experience.
More than 30 years caring for people with allergies.
Founded and run by Dr. Marcello Bossois (CRM-RJ 52.73214-1) and by Dr. Patrícia Schlinkert (CRM/RJ 5274541-3)The Brazil Without Allergies Project adds... more than 30 years of history and more than 450,000 free services, with physical presence at Rio de Janeiro, São Paulo and Paraná, one mobile clinic bus that brings testing and consultations to communities with limited access to specialized care and a platform of telemedicine which connects patients from all states to the same standard of care.
START TODAY
Your expert consultation is just a click away.
I want to join the Diamond Plan.Schedule a teleconsultation
Official telemedicine environment: brasilsemalergia.online
Do you prefer to be served in person?
Our clinical units They conduct consultations, allergy tests, and immunotherapy follow-up with doctors in person:
- Rio de Janeiro: Realengo (West Zone), North Zone, Duke of Caxias, Xerém, New Iguaçu, Itaguaí, Niterói, Iguaba Grande and Saint Peter of the Village (Lakes Region).
- São Paulo: Campo Limpo (South Zone).
- Paraná: Curitiba.
Schedule your in-person appointment. Or check the mobile bus schedule through the customer service center on WhatsApp. (21) 99954-5632.
The indication for immunotherapy, and for any treatment, depends on an individual medical evaluation. This content is for informational purposes only and does not replace consultation with a specialist.
Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.
Conclusion and Summary of Guidelines
In summary, the appropriate approach to Xolair It requires a clear understanding of the immunological mechanisms involved, precise etiological diagnosis, and individualized medical follow-up. Avoiding self-medication and investigating the root cause of symptoms—relying on specialized resources and reliable guidance such as specialized allergy and immunology care when clinically relevant—is the safest way to control flare-ups, prevent complications, and ensure sustainable quality of life.
Scientific references and authoritative sources
The guidelines on this page follow the guidelines and literature of leading international Allergy and Immunology institutions. For further information:




